For a country adding 1400,000 new cancer cases every year, the scale of the crisis alone is staggering. Yet in India, where nearly 40 percent of cancer hospitalizations are financed through borrowings, asset sales, or support from relatives, the economics of survival have long been as brutal as the disease itself.
A treatment course that cost ?8–10 lakh five years ago now runs INR 15-25 lakh in metropolitan hospitals, and for targeted therapies or immunotherapy, the meter climbs further. Founded in 1985 by the late Shri Vijay Batra as part of the Adley Group, Beta Drugs has built its identity around one conviction that: high-quality cancer medicines must also be affordable.
Under the leadership of Rahul Batra, Managing Director & Chairman, and Varun Batra, Joint Managing Director, the company today serves 46 countries with a portfolio of 135- plus SKUs, a deeply integrated manufacturing ecosystem, and a pipeline positioned for significant global expansion.
From being among the first to bring high-cost cancer medicines to market after patent expiry, to pioneering Novel Drug Delivery System (NDDS) formulations that improve patient compliance, the company has consistently placed scientific capability in service of access.
Dual Vision Steering Long-Term Growth
Few pharmaceutical companies are built to hold two things simultaneously, the patience required for long-term scientific investment and the urgency demanded by global expansion. Beta Drugs' leadership model is designed precisely around this tension.
Rahul Batra anchors the organization in strategic depth and a patient-centric philosophy refined over decades. Varun Batra pushes forward, new markets, new partnerships, new capabilities. Together, they have built a company that can think in decades and move in quarters.
This balance matters more in oncology than almost anywhere else in pharma. Regulatory approvals take years. R&D pipelines require sustained investment long before they yield returns. At the same time, the competitive landscape shifts constantly, new molecules, evolving treatment protocols, and markets with vastly different quality expectations.
A leadership model that cannot hold both horizons tends to sacrifice one for the other. Beta Drugs, notably, has not.
Beta Drugs reaches more than 85 percent of corporate and government hospitals across India and has earned a place on Forbes Asia's "200 Best Under a Billion" list for four consecutive yearsRahul Batra, Managing Director & Chairman, Varun Batra, Joint Managing Director
The Push for Smarter Formulations
There is a version of pharmaceutical R&D that is essentially sophisticated copying, waiting for patents to expire and manufacturing generic equivalents. Beta Drugs does some of that. But it does not stop there.
Beyond developing new products, company focuses on optimizing existing therapies through improved formulations, novel drug delivery systems, and differentiated treatment options that enhance efficacy, minimize side effects, and improve patient adherence to therapy specialy for patients who are not able to swallow conventional tablets like Head & Neck cancer patients, elderly patients & pediatric patients. The company has a goal to bridge the gap between innovation and patient access.
The evidence is specific. Beta Drugs became the first Indian company to receive approval for Methotrexate Oral Solution, has launched Megestrol Acetate Suspension, and as far back as 2015, developed in-house Albumin-bound Paclitaxel, a formulation so technically demanding that many larger companies still source it externally.
A robust NDDS pipeline is currently in development, reinforcing that this is a sustained strategic direction rather than a series of isolated wins. An active patient support program has also helped hundreds of patients access treatment they would otherwise have been unable to afford.
Manufacturing Excellence
In oncology, manufacturing is not a back-office function. It is a strategy. Beta Drugs' response to supply chain vulnerability has been methodical, shortening it from both ends. The company's API plant, Adley Labs, supplies 90 percent of its formulations in-house.
A separately established intermediate facility controls Key Starting Materials, or KSMs, shielding production from import disruptions and geopolitical volatility. In 2023-24, Adley Labs cleared a PIC/S audit - a credential that opens doors to regulated markets many Indian manufacturers simply cannot enter.
“Quality is not just a regulatory requirement, it is a fundamental responsibility towards patients whose lives depend on the safety and effectiveness of our medicines. In oncology, even the smallest variation can impact patient outcomes, which is why process standardization, data integrity, and regulatory compliance remain non-negotiable”, says Rahul Batra.
Backward integration also compresses costs at the source, the only sustainable way to make oncology medicines affordable without eroding margins. This has simultaneously made Beta Drugs a recognized contract manufacturing partner for leading pharmaceutical companies across India.
Global Roadmap Rooted in Accessibility
Beta Drugs reaches more than 85 percent of corporate and government hospitals across India and has earned a place on Forbes Asia's "200 Best Under a Billion" list for four consecutive years, recognition that speaks as much to consistency as it does to scale.
The international ambition, however, is where the next chapter gets compelling. Internationally, regulatory approvals span EAEU, Brazil's ANVISA, Colombia's INVIMA, and Mexico's COFEPRIS, with a scheduled EU GMP. Over 600 registrations are in the pipeline across Latin America, Asia- Pacific, MENA, Africa, and the CIS region.
The COFEPRIS approval unlocks Mexico's 1.3-billion-dollar oncology formulation market. EAEU access spans Russia, Kazakhstan, Kyrgyzstan, Belarus, and Armenia simultaneously.
“Our vision is to build a globally respected oncology company that combines scientific innovation, manufacturing excellence, and affordability, making advanced cancer treatments accessible to more patients worldwide. We will continue investing in R&D, complex oncology products, and next-generation therapies while strengthening our presence across regulated and emerging markets”, says Varun Batra.
The future of oncology will continue to be shaped by therapies that are not only clinically effective but also more accessible, patient-friendly, and economically sustainable. As treatment protocols evolve, the need for differentiated formulations, robust manufacturing capabilities, and reliable global supply chains will become increasingly critical.
Beta Drugs has spent nearly four decades building these capabilities through continuous investment in complex oncology formulations, Novel Drug Delivery Systems (NDDS), backward-integrated manufacturing, and stringent quality standards.
With a growing international footprint, a strong product pipeline, and an unwavering commitment to affordability, the company is well positioned to address the evolving needs of cancer care while ensuring that advanced oncology treatments reach more patients across the world.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")